Antidepressiva i graviditeten

Ugeskrift for Laeger

Volumn 173, Issue 15, 2011, Pages 1118-1120

  Pedersen, Lars Henning ^a,b   Videbech, Poul ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79954604499     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Cohen LS, Altshuler LL, Harlow BL et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006;295:499-507.
2. Nielsen RE, Stage KB, Christensen PM et al. Medikamentel behandling af depression under graviditet eller amning. Ugeskr Læger 2007;169:1442-4.
3. Hendrick V, Stowe ZN, Altshuler LL et al. Placental passage of antidepressant medications. Am J Psychiatry 2003;160:993-6.
4. Einarson A, Choi J, Einarson TR et al. Rates of spontaneous and therapeutic abortions following use of antidepressants in pregnancy: results from a large prospective database. J Obstet Gynaecol Can 2009;31:452-6.
5. Wurst KE, Poole C, Ephross SA et al. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 2010;88:159-70.
6. Pedersen LH, Henriksen TB, Vestergaard M et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009;339:b3569.
7. Louik C, Lin AE, Werler MM et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356:2675-83.
8. Kornum JB, Nielsen RB, Pedersen L et al. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. J Clin Epidemiol 2010;2:29-36.
9. Merlob P, Birk E, Sirota L et al. Are selective serotonin reuptake inhibitors cardiac teratogens? Birth Defects Res A Clin Mol Teratol 2009;85:837-41.
10. Aagaard L, Hansen EH. Adverse drug reactions from psychotropic medicines in the paediatric population: analysis of reports to the Danish Medicines Agency over a decade. BMC Res Notes 2010;3:176.
11. Sanz EJ, las-Cuevas C, Kiuru A et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005;365:482-7.
12. Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010;40:1723-33.
13. Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med 2009;163:949-54.
14. Lattimore KA, Donn SM, Kaciroti N et al. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a metaanalysis. J Perinatol 2005;25:595-604.
15. Moses-Kolko EL, Bogen D, Perel J et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005;293:2372-83.
16. Dubnov-Raz G, Koren G, Finkelstein Y. Selective serotonin reuptake inhibitor exposure in pregnancy and neonatal adverse events. Arch Pediatr Adolesc Med 2010;164:394, 394-5.
17. Chambers CD, Hernandez-Diaz S, van Marter LJ et al. Selective serotoninreuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. New Engl J Med 2006;354:579-87.
18. Gentile S, Galbally M. Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review. J Affect Disord 2011;128:1-9.
19. Pedersen LH, Henriksen TB, Olsen J. Fetal. exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 2010;125: e600-8.
20. Oates M. Perinatal psychiatric disorders: a leading cause of maternal morbidity and mortality. Br Med Bull 2003;67:219-29.